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Patients randomised to fingolimod had more severe clini-
cal and MRI disease characteristics at baseline compared 
with IFN β-1b. At Month (M) 18, both treatment groups 
showed improvements in all cognitive parameters. At M18, 
relapse rate, total number and volume of T2/T1 gadolinium-
enhancing lesions were higher with IFN β-1b, as well as the 
percentage brain volume change during the study. Safety 
and tolerability of both treatments were similar to previous 
studies. Both treatments showed improvements in cognitive 
parameters. Fingolimod demonstrated significantly better 
effects on MRI parameters and relapse rate. Imbalance in 
baseline characteristics and the drop-out pattern may have 
favoured IFN β-1b. A longer duration trial may be needed 
to observe the complete expression of differential effects 
on CI scales reflecting the between-groups differences on 
MRI. Although limited in size, the GOLDEN study confirms 
Abstract Cognitive impairment (CI) affects 40–65% 
of multiple sclerosis (MS) patients. This study attempted 
evaluating the effects of fingolimod and interferon beta-
1b (IFN β-1b) on CI progression, magnetic resonance 
imaging (MRI) and clinical outcomes in relapsing–remit-
ting MS (RRMS) patients over 18 months. The GOLDEN 
study was a pilot study including RRMS patients with CI 
randomised (2:1) to fingolimod (0.5 mg daily)/IFN β-1b 
(250 µg every other day). CI was assessed via Rao’s Brief 
Repeatable Battery and Delis–Kaplan Executive Function 
System test. MRI parameters, Expanded Disability Status 
Scale scores and relapses were measured. Overall, 157 
patients were randomised, of whom 30 discontinued the 
study (fingolimod, 8.49%; IFN β-1b, 41.18%; p ≤ 0.0001). 
Members of the GOLDEN study group are listed at the 
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the favourable benefit–risk profile of fingolimod reported in 
previous studies.
Keywords Fingolimod · Interferon beta-1b · Cognitive 
impairment · Brief repeatable battery test · Brain atrophy · 
Delis–Kaplan executive function test
Introduction
Multiple sclerosis (MS) is a progressive demyelinating 
disease of the central nervous system (CNS) that results 
in motor, cognitive and neuropsychiatric impairment [1]. 
Approximately 40–65% of patients with MS experience 
symptoms of cognitive impairment (CI), which can affect 
complex attention, information processing speed, visuospa-
tial memory and executive functions [2, 3]. CI may occur 
early in the disease course and can lead to considerable dete-
rioration in patients’ quality of life [4]. Currently, there is no 
proven effective rehabilitation programme or symptomatic 
treatment for MS-related CI [5, 6].
Disease-modifying therapies (DMTs) approved for MS 
treatment have proven efficacy in terms of clinical (relapses 
and disability progression) and magnetic resonance imaging 
(MRI) (lesion formation and atrophy evolution) parameters 
[7–9]. However, most of the pivotal, randomised trials on 
DMTs did not include cognitive endpoints; thus, the evi-
dence on the effect, in particular on the effect size, of these 
DMTs on CI is inconclusive. Moreover, in the clinical tri-
als that did include cognitive assessment, the assessment 
was often limited to one or two tests for specific cogni-
tive domains, like the Paced Auditory Serial Addition test 
(PASAT), and did not comprehensively assess all cognitive 
domains impacted by MS [5]. A complete assessment by 
means of a battery of validated tests, such as the Rao’s Brief 
Repeatable Battery (BRB) [10] or the Brief International 
Cognitive Assessment for MS (BICAMS) [11], would be 
important, given the multiplicity of cognitive domains 
impacted by MS-related CI. Furthermore, evaluation of ver-
bal and non-verbal executive functions, by scoring patients’ 
performance on a specific scale like the Delis–Kaplan Exec-
utive Function System (DKEFS) [12] scale or the Stroop 
Test [13], is also important for complete assessment of CI.
CI is often accompanied by depression, which may fur-
ther worsen CI and influence its correct evaluation. There-
fore, assessment of depression in these patients using a 
validated scale like the Montgomery–Asberg Rating Scale 
(MADRS), a widely known clinician-rated assessment tool, 
is recommended [14].
Several studies also suggest a correlation between MRI 
measures (white matter and grey matter lesion number 
and/or volume, global brain and grey matter volume) and 
CI, which is yet to be fully assessed in randomised, thera-
peutic trials [2, 15–17].
Once-daily oral fingolimod  (Gilenya®, Novartis Pharma 
AG) is a sphingosine-1-phosphate (S1P) receptor mod-
ulator approved for the treatment of relapsing forms of 
MS [7, 18]. Fingolimod acts by reducing the number of 
recirculating autoreactive T-cells entering the CNS and 
destroying the myelin sheath, via reducing egress of these 
lymphocytes from the lymph nodes. Unlike interferons 
(IFNs), which have an immunomodulatory effect but lack 
any direct effects on CNS cells, fingolimod crosses the 
blood–brain barrier and acts directly on the S1P recep-
tors located on these cells, leading to reduction of reactive 
activation of glia (which may favour naturally occurring 
remyelination) [19]. This mechanism of action might be 
responsible for the effects of fingolimod on slowing brain 
atrophy observed in previous studies (which in turn is pos-
sibly associated with CI) [7, 18]. In phase III pivotal stud-
ies, fingolimod-treated MS patients developed less brain 
atrophy versus patients receiving placebo both at Year 1 
(−0.50 vs. −0.65%) and at Year 2 (−0.84 vs. −1.31%) in 
the FREEDOMS study [18], and versus patients receiv-
ing interferon beta-1a (IFN β-1a) over 1 year (−0.31 vs. 
−0.45%) in the TRANSFORMS study [7].
The effect of fingolimod on CI in patients with MS has 
been assessed using the PASAT in two pivotal phase III, 
randomised studies—FREEDOMS and TRANSFORMS. 
In both these studies, a trend towards greater propor-
tion of correct responses on the PASAT-3 was observed 
in patients treated with fingolimod compared with those 
receiving placebo (FREEDOMS) or IFN β-1a (TRANS-
FORMS, where the difference versus IFN β-1a was sig-
nificant with p = 0.049) [20]. An observational, single-
centre, open-label, 1-year prospective study conducted by 
Barak et al. suggested that fingolimod confers cognitive 
stability in patients with active relapsing–remitting MS 
(RRMS) [21]. Fingolimod has also shown positive effects 
on cognitive parameters in various clinical trials and real-
world studies [22–24]. However, these effects still need 
to be assessed in a comprehensive way with respect to all 
the cognitive domains that are altered during the course 
of MS as well as in comparison to the effects of standard-
of-care DMTs.
The 18-month ‘GOLDEN’ (Fingolimod on cognitive 
symptoms and brain atrophy) study aimed at evaluating 
the effects of treatment with fingolimod and IFN β-1b on 
CI progression using the BRB and DKEFS scale as well 
as on MRI and clinical outcomes in patients with RRMS. 
This side-by-side evaluation was designed to provide pilot 
evidence for the effect of fingolimod and IFN β-1b on cog-
nitive, MRI and clinical outcomes. A direct comparison 
between fingolimod and IFN β-1b was not a prespecified 
objective of this study.




The GOLDEN study (ClinicalTrials.gov identifier 
NCT01333501) was an 18-month multicentre, open-label, 
rater-blinded, randomised, parallel-group pilot study con-
ducted in patients with RRMS. Eligible patients were aged 
18–60 years and diagnosed with RRMS (per the 2005 
revised McDonald criteria [25]) with active disease and 
CI at screening. Active disease was defined as at least one 
clinical relapse in the past year, or two clinical relapses 
in the past 2 years if there were signs of disease activity 
in one brain MRI scan performed in the past 6 months. 
CI was defined as ≥ 1 test of the Rao’s BRB with scores 
below the tenth percentile of age- and gender-based nor-
mative data. Key exclusion criteria included unsatisfactory 
response with multi-weekly IFNs (IFN β-1a/b), hyperac-
tive forms of MS, Expanded Disability Status Scale 
(EDSS) score > 5.0, acute MS relapse < 30 days before 
screening, prior or current diagnosis of major depression 
according to the Diagnostic and Statistical Manual of 
Mental Disorders—Text Revision (DSM-IV-TR) and his-
tory of any chronic disease of the immune system other 
than MS.
All patients provided written informed consent before 
enrolment. The study was conducted in accordance with 
the International Conference on Harmonisation Guidelines 
for Good Clinical Practice and the Declaration of Helsinki 
[26, 27]. The study was conducted at 36 study centres, 
28 in Italy (22 recruiting) and 8 in Germany (4 recruit-
ing), and the protocol was approved by the Independent 
Ethics Committee or Institutional Review Board at each 
centre. The study included a 1-month screening phase to 
determine eligibility. At baseline, eligible patients were 
randomised (2:1) to receive oral fingolimod (0.5 mg/day) 
or subcutaneous IFN β-1b (250 µg every other day; Fig. 1). 
Study visits for patient clinical assessment were scheduled 
at screening, baseline and Months 3, 6, 9, 12, 15 and 18 
of treatment.
Efficacy assessments
CI was assessed using the BRB of neuropsychological tests 
in MS [28], comprising five tests: Selective Reminding Test 
[SRT; includes long-term storage (SRT-LTS), consistent 
long-term retrieval (SRT-CLTR) and delayed recall (SRT-
d)]; 10/36 Spatial Recall Test (10/36 SPART) [total cor-
rect responses (10/36 SPART-T) and delayed recall (10/36 
SPART-DR)]; Symbol Digit Modalities Test (SDMT); 
PASAT and Word List Generation (WLG) test performed at 
screening, Month 9 and Month 18. All BRB tests have been 
validated in Italian and German and are available in two 
alternate forms (A and B), which were administered accord-
ing to the scheme A–B–A to reduce the practice effect. Gore-
tti et al. have suggested that, similar to other languages, the 
Italian B version of the BRB test may be easier than version 
A but also suggested that the application of the normative 
values provided in their study can overcome this issue [29]. 
We therefore considered that the BRB versions A and B are 
comparable only when the data are normalised. Moreover, 
normalisation of BRB in German is available only for ver-
sion A.
Executive functions were assessed using the DKEFS-
Sorting test [30], one of the nine tests presented in the 
DKEFS manual, at screening, Month 9 and Month 18. The 
DKEFS test consisted of two testing procedures: free sort-
ing and sort recognition. In free sorting, six scores were 
obtained: confirmed correct sorts for card sets 1 and 2 (or 
3 and 4 for version B), sum of confirmed correct sorts, free 
sorting description score for card sets 1 and 2 (or 3 and 4 for 
version B) and sum of free sorting description scores. In sort 
recognition, a description score for card sets 1 and 2 (or 3 
Fig. 1  Study design. BRB 
Rao’s brief repeatable battery, 
DKEFS Delis–Kaplan executive 
function system, eod every 
other day, MADRS Montgom-
ery–Asberg Depression Rating 
Scale, MRI magnetic resonance 
imaging
0.5 mg/day fingolimod
250 µg/eod IFN β-1b
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and 4 for version B) as well as the sum of description scores 
of both sets were obtained.
The MADRS [14] was used to assess depression at 
screening, Month 9 and Month 18.
MRI was performed locally at the participating centres 
on 1.5 T (or higher) scanners according to a prespecified 
protocol provided by the central reading facility (Neuroim-
aging Research Unit, Institute of Experimental Neurology, 
San Raffaele Scientific Institute, Milan, Italy). MRI param-
eters [T2-hyperintense, T1-hypointense and T1-enhancing 
lesions, normalised brain volume (NBV) and percentage 
brain volume change (PBVC) versus screening scan] were 
assessed (using central reading) at screening and Month 18. 
The identification of white matter lesions was performed by 
consensus of two experienced observers, and the volume of 
the identified lesions was measured using a semiautomated 
segmentation technique based on local thresholding (Jim 6.0; 
Xinapse System, UK). NBV at screening and PBVC during 
the follow up were measured on precontrast 3D T1-weighted 
images, using the SIENAx and SIENA software.
Patients were assessed for MS relapses during the course 
of the study.
EDSS scores were assessed by local raters, specifically 
trained to minimise variability, at screening, Month 9 and 
Month 18.
Safety assessments
Safety assessments included reporting of adverse events 
(AEs), serious AEs (SAEs), vital signs, physical/neurologi-
cal examinations, skin examination, laboratory examina-
tions, electrocardiogram (ECG) monitoring (as required) 
and ophthalmologic examinations.
AEs, SAEs and vital signs were assessed at each study 
visit. Physical examinations were performed at screening 
and Months 6, 12 and 18; ophthalmologic examinations 
were performed at screening and Months 3, 6 and 18; and 
skin examinations were performed at screening and Month 
18.
Statistical analysis
For the efficacy data analysis, the full analysis set (FAS) 
population was considered instead of the per-protocol pop-
ulation because of the high drop-out rate, particularly in 
the IFN β-1b group. The FAS population included all ran-
domised patients who received at least one dose of the study 
drug and had at least one post-baseline assessment of both 
primary efficacy variables (i.e., non-missing information on 
BRB and DKEFS-Sorting test) without any major protocol 
deviations. The safety population included all randomised 
patients who received at least one dose of the study drug.
Continuous data were summarised by mean, standard 
deviation (SD), median, interquartile range, minimum 
and maximum, and 95% confidence limits (CLs), where 
applicable. Categorical data were presented by absolute 
and relative frequencies (n and %) or contingency tables. 
Homogeneity tests were run to assess differences between 
groups at screening/baseline. The normality of continuous 
variables was evaluated by means of a Shapiro–Wilk test 
to perform the t test (in case of normal data distribution) or 
the Wilcoxon–Mann–Whitney test (in case of non-normal 
data distribution).
Chi square tests were performed for categorical vari-
ables, or Fisher’s exact test for cell frequencies < 5.
Differences between groups in each of the BRB 
tests were analysed by means of analysis of covariance 
(ANCOVA) on raw scores (no a priori data normalisation 
of raw scores based on age/gender and education), with 
propensity score as an independent variable. The following 
variables were considered in the propensity score adjust-
ment: EDSS score at screening, disease duration, naïve or 
treated patients’ status, MADRS total score at screening, 
T2 lesion volume (LV), T1 hypointense LV and number 
of altered BRB tests at screening.
An ANCOVA model was applied to assess the differ-
ences between groups in MRI variables, except for the 
number of T1-enhancing lesions and T2-hyperintense 
lesions, considering propensity score as an explanatory 
variable and screening value as the covariate. The pro-
pensity score analysis considered the following factors: 
EDSS score, disease duration, naïve or treated patients, 
depression (MADRS score) and number of altered cogni-
tive tests. Differences between groups in number of T1 
gadolinium-enhancing (Gd+) lesions and new T2 lesions 
were assessed by means of a negative binomial regres-
sion model, including the same propensity score vari-
ables applied for the ANCOVA model on the other MRI 
variable.
Differences between groups in MADRS scores overtime 
were analysed by means of a mixed model for repeated 
measures (MMRM). The explanatory variables in the lon-
gitudinal model included treatment, visit, treatment-by-
visit interaction, missing data pattern (completers, miss-
ing at Month 9, missing at Month 18), propensity score 
and corresponding baseline. The propensity score analy-
sis considered the following factors: EDSS score, disease 
duration, naïve or treated patients, number of altered tests, 
T2 LV and T1 hypointense LV.
The correlation between each BRB test and each MRI 
variable was performed using Pearson correlation in case 
of normal distribution of both the considered variables, or 
Spearman correlation otherwise.
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Results
Patient disposition, demographic, and baseline 
characteristics
In total, 198 patients were enrolled and screened in the 
GOLDEN study, of whom 157 were randomised (2:1) to 
receive either fingolimod (n = 106) or IFN β-1b (n = 51). 
Overall, 30 of the randomised patients discontinued the 
study: 9 (8.49%) patients from the fingolimod group and 
21 (41.18%) patients from the IFN β-1b group (p ≤ 0.0001) 
(Fig. 2).
The safety population comprised 151 patients (fingoli-
mod, 104; IFN β-1b, 47), whereas the FAS population com-
prised 108 patients (fingolimod, 80; IFN β-1b, 28). Approxi-
mately 50% of the patients in the FAS were treatment naïve 
(fingolimod, 47.5%; IFN β-1b, 53.57%; Table 1). The most 
recent previous treatments included glatiramer acetate, IFN 
β-1a, IFN β-1b, natalizumab, azathioprine and mitoxantrone.
Contrary to the safety population where baseline char-
acteristics were similar across the two treatment groups, 
in the FAS population, patients randomised to receive fin-
golimod had higher number of relapses in the past 2 years 
(p = 0.0191), higher EDSS scores (p = 0.0202), lower NBV 
(p = 0.0452) and worse cognitive test scores [PASAT-3 
(p = 0.0105) and SDMT (p = 0.0183)] compared with the 
IFN β-1b group (Table 1).
There were statistically significant differences between 
the baseline PASAT and SDMT (and WLG) scores of 
patients who completed the study versus those who dropped 
out of the study in the IFN β-1b group: in this group, patients 
who later dropped out had more severe baseline scores than 
the completers, whereas this effect was not observed for the 
patients in the fingolimod group (only a non-statistically sig-
nificant trend was noted for SRT; Fig. 3).
The total duration of treatment exposure was 
537.00  ±  105.77 (range 4–650) days for fingolimod 




For the BRB test, both treatment groups showed improve-
ments in mean changes of all parameters from screening to 
Month 18: SRT-d (p = 0.0163 for fingolimod; p = 0.3270 
for IFN β-1b), PASAT-2 (p  =  0.0002 for fingolimod; 
p = 0.0413 for IFN β-1b), PASAT-3 (p < 0.0001 for fin-
golimod; p = 0.0022 for IFN β-1b), SDMT (p = 0.0540 for 
fingolimod; p = 0.0445 for IFN β-1b), SPART (p = 0.0058 
for fingolimod; p  =  0.0009 for IFN β-1b), SRT-CLTR 
(p = 0.0001 for fingolimod; p = 0.1246 for IFN β-1b), SRT-
LTS (p < 0.0001 for fingolimod; p = 0.0534 for IFN β-1b), 
SPART-d (p = 0.0502 for fingolimod; p = 0.2210 for IFN 
β-1b) and WLG (p = 0.5017 for fingolimod; p = 0.8128 for 
IFN β-1b) (Fig. 4a). No significant differences were detected 
between the treatment groups in the mean changes in all 
parameters from screening to Month 18.
Executive function
Similar to the BRB test, both treatment groups showed 
improvements in the mean changes from screening to 
Month 18 for the components of the DKEFS Sorting test 
(Fig. 4b). No significant differences were detected between 
Fig. 2  Patient disposition. AE 
adverse event, IFN β-1b inter-
feron beta-1b, RRMS relapsing–
remitting multiple sclerosis
RRMS patients assessed for eligibility (n=198)
RRMS patients who underwent randomisation (n=157)
Randomised to fingolimod (n=106) Randomised to  IFN β-1b (n=51)
97 fingolimod-treated patients 
completed the study
30 IFN β-1b-treated patients 
completed the study
9 patients discontinued
 3 (33.3%) discontinued due to AEs
 2 (22.2%) had abnormal laboratory values
 1 (11.1%) had unsatisfactory   
 therapeutic effect
 3 (33.3%) subjects withdrew consent
21 patients discontinued
 1 (4.8%) discontinued due to AEs
 1 (4.8%) had abnormal laboratory values
 7 (33.3%) had unsatisfactory   
 therapeutic effect
 12 (57.1%) subjects withdrew consent
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the treatment groups in the mean changes from screening to 
Month 18 for components of DKEFS-Sorting test.
Depression
The MADRS total score was higher (though not signifi-
cantly) in the fingolimod group at screening (10.77 ± 7.34 
vs. 7.93 ± 6.24; p = 0.0806). At Month 18, fingolimod-
treated patients still exhibited higher scores compared 
with IFN β-1b-treated patients; however, changes versus 
screening indicated slight improvement only in the fin-
golimod group [−0.68 ± 7.57, 95% CL (− 2.45, 1.08) 
versus a change of 0.30 ± 5.63, 95% CL (− 1.93, 2.52) 
Table 1  Baseline 
characteristics of patients 
included in the FAS
Data represent mean (SD) unless specified otherwise
EDSS expanded disability status scale, FAS full analysis set, IFN β-1b interferon beta-1b, MADRS Mont-
gomery–Asberg rating scale, MRI magnetic resonance imaging, MS multiple sclerosis, PASAT paced audi-
tory serial addition test, SD standard deviation, SDMT symbol digit modalities test, SPART 10/36 spatial 
recall test, SPART-d 10/36 spatial recall test-delayed recall, SRT-LTS selective reminding test-long-term 
storage, SRT-CLTR selective reminding test-consistent long-term retrieval, SRT-d selective reminding test-
delayed recall, WLG word list generation
*Number of relapses in the past 2 years, EDSS score at baseline and cognitive test scores (PASAT and 
SDMT) were statistically significant, indicating that IFN β-1b group patients had more severe disease than 
fingolimod group patients
a Wilcoxon two-sample test
b Chi-square
c t test
d Negative binomial regression model
e For safety population
Fingolimod (n = 80) IFN β-1b (n = 28) p value
Patient demographics
 Age at screening, years 40.23 (9.09) 37.64 (9.29) 0.2195a
 Female, n (%) 57 (71.25) 19 (67.86) 0.7351b
 Caucasiane, n (%) 79 (98.75%) 18 (100.00%) –
Disease characteristics
 Age at MS diagnosis, years 35.2 (9.22) 32.89 (8.10) 0.2572a
 Disease duration, years 4.97 (6.67) 4.71 (6.47) 0.5032a
 Number of relapses in the past year 1.45 (0.79) 1.18 (0.48) 0.1193a
 Number of relapses in the past 2 years* 1.90 (0.84) 1.54 (0.84) 0.0191a
 EDSS score at screening* 2.78 (1.34) 2.09 (1.05) 0.0202a
 Treatment-naïve patients, n (%) 38 (47.50) 15 (53.57) 0.5802b
MRI variables
 Normalised brain volume, mL* 1391 (94) 1433 (99) 0.0452c
 Volume of total T2 lesions  (mm3) 10813.00 (10425.76) 7509.21 (7045.94) 0.1770a
 Volume of total T1 hypointense lesions  (mm3) 4076.60 (5317.53) 2090.54 (2217.19) 0.1419a
 Volume of total T1 enhancing lesions  (mm3) 63.95 (158.33) 76.89 (146.32) 0.6252a
 Number of total T1 enhancing lesions 0.75 (1.15) 0.89 (1.91) 0.6260d
Cognitive parameters (raw scores)
 SRT-LTS 32.35 (14.36) 37.04 (15.31) 0.1469c
 SRT-CLTR 22.54 (14.06) 29.36 (17.30) 0.0616a
 SPART 16.50 (4.78) 17.61 (5.23) 0.1629a
 SDMT* 40.89 (14.30) 47.39 (16.14) 0.0183a
 PASAT-3* 30.15 (13.03) 37.82 (14.49) 0.0105c
 PASAT-2 23.31 (12.59) 27.96 (12.76) 0.0515a
 SRT-d 6.48 (2.86) 7.18 (2.89) 0.2670c
 SPART-d 5.80 (2.23) 6.29 (2.34) 0.3354a
 WLG 19.68 (5.63) 21.25 (6.77) 0.2639a
 MADRS 10.77 (7.34) 7.93 (6.24) 0.0806a
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in the IFN β-1b group], although the difference was not 
statistically significant (p = 0.3291).
MRI results
T2 LV at screening was higher in the fingolimod group 
versus the IFN β-1b group (p = 0.1770); although the 
mean T2 LV decreased in both groups from screening to 
Month 18, when taking the deltas into account, i.e. only 
patients who had both values, on average it increased from 
screening to Month 18 in both treatment groups (Fig. 5a). 
At Month 18, patients in the IFN β-1b group presented 
with more new T2 lesions (3.33 ± 4.44 vs. 1.25 ± 2.05) 
than those in the fingolimod group (p = 0.0276 between 
groups).
The number and volume of Gd+ lesions at screening 
were similar in the two groups; both number and vol-
ume decreased in patients treated with fingolimod (sig-
nificantly for the number of lesions, p = 0.0316) and 
increased in patients treated with IFN β-1b. The between-
group difference was significant for the number of T1 
Gd+ lesions (p = 0.0290; Fig. 5b, c).
NBV at screening was significantly lower in the fin-
golimod group versus the IFN β-1b group (1391 vs. 
1433  mL; p  =  0.0452). During the study, the PBVC 
from screening to Month 18 in the IFN β-1b group 
(−0.96% ± 0.71%) was larger than that in the fingolimod 
group (−0.60% ± 0.83%; Fig. 5d), and the between-group 
difference was statistically significant in favour of fin-
golimod (p = 0.0166).
No significant correlation was found between the 
effects of treatment on MRI parameters and on the vari-
ous tests of the BRB or DKEFS.
Relapses and EDSS
The proportion of patients with at least one relapse dur-
ing the study period was significantly higher in the IFN 
β-1b group than in the fingolimod group (31.91 vs. 15.38%, 
p = 0.0199; Table 2). Moreover, the annualised relapse rate 
was also higher in the IFN β-1b group than in the fingolimod 
group (0.39 vs. 0.12; Fig. 6).
EDSS scores remained virtually stable over the 18-month 
study period, with very small changes in scores at Month 18 
versus screening, of 0.12 ± 0.84 [95% CL (− 0.07, 0.31)] 
in the fingolimod group and 0.19 ± 0.54 [95% CL (− 0.03, 
0.40)] in the IFN β-1b group.
Safety results
Overall, AEs were reported in 79.81% of patients treated 
with fingolimod and 59.57% treated with IFN β-1b 
(Table 3a). No deaths were reported during the study.
The proportion of patients with SAEs was higher in 
the fingolimod group versus the IFN β-1b group (8.65 vs. 
2.13%), with one SAE suspected of being related to the 
study treatment in the fingolimod group (second-degree 
atrioventricular block after first dose of the drug, in a 
patient who underwent overnight hospitalisation and then 
continued treatment with fingolimod without problems), 
while the proportion of patients discontinuing the study 
due to AEs was higher in the IFN β-1b group (6.38 vs. 
4.81%). The most commonly reported (first five) system 
organ classes (SOCs) in both groups were ‘infections and 
infestations’ (primarily nasopharyngitis and influenza), 
‘investigations’ (primarily alanine aminotransferase 
[ALT], blood cholesterol and transaminase increases for 
b1-β NFIdomilogniF
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Fig. 3  SDMT and PASAT scores at screening for patients who 
completed the treatment versus those who dropped out of the study 
(safety population). IFN β-1b interferon beta-1b, PASAT paced audi-
tory serial addition test, SDMT symbol digit modalities test. The fig-
ure represents mean values of PASAT and SDMT raw scores. The p 
value was calculated using the t test for SDMT and PASAT-2 in IFN 
group and PASAT-3 in fingolimod group; otherwise, the Wilcoxon 
two-sample test was used
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fingolimod; transaminase, blood triglyceride and cho-
lesterol increases for IFN β-1b), ‘nervous system disor-
ders’ (mostly headache for fingolimod and MS relapse 
for IFN β-1b), ‘gastrointestinal disorders’(only one case 
of diarrhoea was thought to be related to treatment, in 
the fingolimod group), ‘general disorders and administra-
tion site conditions’ (fever, fatigue and influenza-like ill-
nesses more frequent in the IFN β-1b group). Of the 11 
cases of the SOC ‘Skin and subcutaneous tissue disorders’ 
that have been reported only among patients treated with 
fingolimod, two were considered possibly related to the 
treatment: one case of psoriasis and one case of alopecia 
(Table 3b).
Discussion
Cognitive dysfunction is a common clinical problem in MS 
and is associated with functional impairment leading to dete-
rioration in patients’ quality of life [4]. Thus, a number of 
studies have been performed on cognitive dysfunction in 
patients with MS; however, most of the evidence supporting 
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Fig. 4  Cognitive impairment test results a Rao’s BRB test: 
ANCOVA LS mean changes Month 18 versus screening (FAS popu-
lation) *p < 0.05; **p < 0.01; ***p < 0.001. ANCOVA analysis of 
covariance, BRB brief repeatable battery, FAS full analysis set, IFN 
β-1b interferon beta-1b, LS least squares, M month, PASAT paced 
auditory serial addition test, SDMT symbol digit modalities test, SE 
standard error, SPART 10/36 spatial recall test, SPART-d 10/36 spatial 
recall test-delayed recall, SRT-LTS selective reminding test-long-term 
storage, SRT-CLTR selective reminding test-consistent long-term 
retrieval, SRT-d selective reminding test-delayed recall, WLG Word 
List Generation, b DKEFS-sorting test: ANCOVA model estimated 
mean (LSmean) changes at Month 18 versus screening (FAS popula-
tion). *p  <  0.05; **p  <  0.01. Note: Condition  1—free sorting: fin-
golimod 66, IFN β-1b 27. Condition 1—free sorting description: fin-
golimod 65, IFN β-1b 27. Condition 2–sort recognition: fingolimod 
50, IFN β-1b 21. ANCOVA analysis of covariance, DKEFS Delis–
Kaplan executive function test, FAS full analysis set, IFN β-1b inter-
feron beta-1b, LS least squares, M month
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observational, often uncontrolled/non-randomised, studies 
using single tests that typically assess only one cognitive 
domain [5, 31–33]. Moreover, controlled trials investigat-
ing the effect of DMTs in MS were primarily designed to 
evaluate clinical outcomes, and cognitive dysfunction was 
assessed as a secondary outcome or only in a subgroup of 
patients [5].
This is the first randomised, double-blind study to pro-
spectively and comprehensively assess CI in MS patients 
treated with fingolimod versus an active control (IFN β-1b). 
A number of characteristics made our study design quite 
robust in assessing CI in MS patients over the given period 
of time. First, as described earlier, we have used the full 
BRB test, which is a sensitive and widely used tool in clini-
cal practice, and also assesses executive functions with the 
DKEFS scale. Second, patients were included in the study 
only if they already presented CI at screening. This ‘enrich-
ment design’ is important, since it is known that preserved 
cognitive function can remain stable over a long time in MS, 
whereas incipient cognitive decline seems to be widespread 
and progressive in nature [34]. Thus, trials in cognitively 
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Fig. 5  MRI measures. a Total T2 lesion volume  (mm3), b num-
ber of T1 Gd+ lesions, c volume of T1 Gd+  lesions  (mm3), and d 
brain volume (mL). p values for the changes were calculated using an 
ANCOVA model, except for the number of T1 Gd+  lesions, which 
was computed by using a negative binomial regression model. At 
baseline, the p values were calculated using the Wilcoxon two-sam-
ple test, except for the brain volume, which was calculated using the 
t test. *p < 0.05 within group. ANCOVA analysis of covariance, Gd+ 
gadolinium enhancing, IFN β-1b interferon beta-1b, M month, MRI 
magnetic resonance imaging
Table 2  MS relapse (safety population)
*Chi-square test
Fingolimod (n = 
104)
IFN β-1b (n = 47) p value*
No. of patients 
with at least one 
relapse
16 (15.38%) 15 (31.91%) 0.0199
Of above, patients with
 1 relapse 13 (81.25%) 10 (66.67%)
 2 relapses 2 (12.50%) 3 (20.00%)





















Fig. 6  MS relapse rate (safety population). IFN β-1b interferon beta-
1b, MS multiple sclerosis
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differences in CI that will accumulate in such a population 
over the course of the study, particularly if the study dura-
tion is short and does not run over many years, whereas 
these chances were maximised with our enriched population 
design. Third, in order to prevent the learning of specific 
test stimuli and thus potentially mitigate practice effects, all 
the tests of the BRB were provided at screening, Month 9 
and Month 18 in two alternate forms (A and B, scheme of 
administration: A–B–A). Fourth, a standard MRI acquisition 
protocol was followed across all the sites to ensure uniform 
quality of the scans across the sites; scans were then ana-
lysed at a central MRI evaluation centre by physicians who 
were unaware of the study-group assignments.
This notwithstanding, the following factors were taken 
into account when interpreting the results of our study, par-
ticularly with regard to the less objective endpoints like cog-
nitive scales, compared to the more objective endpoints like 
MRI. In addition, one has to remember that the study was 
neither powered nor designed to serve as a direct comparison 
between fingolimod and IFN β-1b on cognitive scales, but 
rather to provide side-by-side, pilot evidence. First of all 
(and contrary to the safety population, where there were no 
differences between the treatment groups, which indicates 
that randomisation did work), in the FAS population patients 
in the fingolimod group had more severe disease character-
istics at baseline compared with patients in the IFN β-1b 
group, significantly so in terms of number of relapses in the 
past 2 years, EDSS score, NBV and cognitive test scores 
(PASAT and SDMT). Second, as expected, a considerably 
higher percentage of patients treated with IFN β-1b versus 
fingolimod prematurely discontinued treatment (41.18 vs. 
8.49%), with the main reasons for discontinuation being 
‘unsatisfactory therapeutic effect’ and ‘withdrawal of con-
sent’. One implication is that patients in the IFN β-1b group 
with more severe disease abandoned the trial, as confirmed 
by the difference between the randomised population and 
the FAS population. A second implication is that patients 
in the IFN β-1b group who completed the study and had 
Month 18 cognitive scores available were most probably 
those who were responding better to that treatment com-
pared to the fingolimod group. This is supported by the sta-
tistically significant differences between the baseline PASAT 
Table 3  AEs and SAEs in the safety set
AE adverse event, IFN β-1b interferon beta-1b, SAE serious adverse event
*Chi-square test
n (%) Fingolimod (n = 104) (%) IFN β-1b (n = 47) (%) p value*
(a) Summary of AEs (safety population)
Number of patients with at least one AE 83 (79.81) 28 (59.57) 0.0091
Number of patients with at least one SAE 9 (8.65) 1 (2.13) 0.1354
Number of patients with at least one AE suspected to be study 
drug related
37 (35.58) 10 (21.28) 0.0789
Number of patients with at least one AE leading to discontinua-
tion
5 (4.81) 3 (6.38) 0.6891
SOC ≥ 5%, n (%) Fingolimod (n = 104) (%) IFN β-1b (n = 47) (%)
(b) AEs by SOC ≥ 5% (safety population)
Number of patients with at least one AE 83 (79.81) 28 (59.57)
Blood and lymphatic system disorders 7 (6.73) 0
Eye disorders 8 (7.69) 1 (2.13)
Gastrointestinal disorders 22 (21.15) 5 (10.64)
General disorders and administration site conditions 17 (16.35) 10 (21.28)
Infections and infestations 29 (27.88) 9 (19.15)
Injury, poisoning and procedural complications 6 (5.77) 3 (6.38)
Investigations 26 (25.00) 9 (19.15)
Metabolism and nutrition disorders 8 (7.69) 2 (4.26)
Musculoskeletal and connective tissue disorders 11 (10.58) 5 (10.64)
Nervous system disorders 19 (18.27) 12 (25.53)
Psychiatric disorders 13 (12.50) 6 (12.77)
Renal and urinary disorders 6 (5.77) 4 (8.51)
Respiratory, thoracic and mediastinal disorders 6 (5.77) 3 (6.38)
Skin and subcutaneous tissue disorders 11 (10.58) 0
Vascular disorders 6 (5.77) 1 (2.13)
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and SDMT (and WLG) scores of patients who completed 
the study versus those who dropped out of the study in the 
IFN β-1b group: in this group patients who later dropped 
out had more severe baseline scores than the completers, 
whereas this effect was not observed for the patients in the 
fingolimod group (only a non-statistically significant trend 
was noted for SRT; Fig. 3).
Our results show that both fingolimod and IFN β-1b 
improved all cognitive domains affected by MS, as evalu-
ated through the various tests of the BRB (SRT-d, SRT-LTS, 
SRT-CLTR, SPART, SPART-d, SDMT, PASAT and WLG) 
with some differences in the improvement pattern. Fingoli-
mod showed the best effect on PASAT and SRT scores, 
whereas IFN β-1b showed the best effect on SDMT scores. 
In this regard, it is worth noting that PASAT is a difficult and 
demanding test of the battery, relatively more difficult than 
the SDMT, and is sensitive even to early cognitive changes 
in patients where room for improvement is still limited [35, 
36]. A longitudinal correlational research study suggested 
that PASAT is particularly sensitive to inflammatory activ-
ity measured by Gd+ enhancement in otherwise physically 
stable patients with MS [37]. Hence, the observed effect of 
fingolimod on PASAT in this study is consistent with the 
effect observed on Gd+ lesions.
In general, our results are supported by previous studies 
evaluating the effect of IFN or fingolimod on CI in real-
world setting using a non-randomised design. A 3-year, 
open-label, prospective, observational study [COGnitive 
Impairment in Multiple Sclerosis (COGIMUS)] showed 
that the proportion of cognitively impaired patients treated 
with IFN β-1a remained stable over the 3 years of treatment 
in at least three tests of the BRB and the Stroop Color-Word 
Task [33]. In another 1-year, open-label study, treatment 
with IFN β-1b in RRMS patients led to improved perfor-
mance in the complex attention, concentration and visual 
learning and recall domains compared with patients with 
RRMS matched for neurological disability [31]. In a post 
hoc analysis of pooled data from a fingolimod phase III trial 
in patients with RRMS, fingolimod treatment resulted in 
early and sustained improvement in cognition, as measured 
by the change in PASAT-3 scores over 6, 12 and 24 months 
[23]. Results of a multicentre, examiner-blinded, prospec-
tive trial also showed significant improvement in cognitive 
function from the sixth month of initiation of fingolimod 
in patients with RRMS [24]. Additionally, real-world stud-
ies in patients with RRMS have shown a positive impact 
of fingolimod treatment on cognitive parameters [22]. In a 
study comparing effectiveness of natalizumab and fingoli-
mod treatment on cognitive functions by using the BRB tests 
in patients with RRMS from clinical practice, fingolimod 
was found to be more effective than natalizumab in improv-
ing cognitive function [38]. However, our study provides 
novel information on the topic. Namely, we show that there 
is not necessarily any direct correlation between the effects 
of a given treatment on MRI parameters (particularly on 
brain atrophy, which in turn has been shown to correlate 
with a beneficial effect on CI) and on the multiplicity of tests 
that compose the BRB or DKEFS. In general, studies have 
identified a significant correlation between MRI measures 
and CI [7, 39, 40] and, more specifically, studies suggest a 
robust correlation between cognitive deficits and irrevers-
ible tissue loss in the brain, usually measured in terms of 
global and regional atrophy [41]. In our study, fingolimod 
showed better results than IFN β-1b on all MRI parameters, 
brain atrophy and clinical parameters (relapse rate and EDSS 
score). This is supported by previous studies in which fin-
golimod was associated with early and consistent reduction 
in brain volume loss, compared with both placebo and intra-
muscular IFN β-1a [42]. On the other hand, both fingolimod 
and IFN β-1b improved all cognitive domains affected by 
MS, as evaluated through the various tests of the BRB, with 
some differences in the improvement pattern. Apart from 
the confounding effects of the difference in baseline sever-
ity and drop-out patterns across the two groups, which hold 
true both for the effects on cognitive scales and on MRI, 
this difference in effects on MRI versus BRB may also be 
due to other factors, including better sensitivity of MRI (the 
most sensitive tool to capture early tissue loss quantitatively 
and independent of any practice effects [43]) compared with 
cognitive scales for the detection of changes in endpoints 
supposed to be correlated (such as CI and atrophy), or to 
different sensitivity across the individual scales to changes 
in similar or different cognitive domains. Finally, the lim-
ited duration of the trial (18 months) may have impacted on 
the possibility of observing the complete expression of dif-
ferential effects between the treatment groups on cognitive 
impairment scales reflecting the between-groups differences 
on MRI. Trials of longer duration may therefore be required 
to assess this aspect.
This absence of a firm correlation (also due to the high 
number of confounding effects and biases in assessing CI) 
also shows that effects of interventions (pharmacologic or 
non-pharmacologic) on functional cognitive capacity should 
be shown directly and cannot be deduced from effects on 
brain volumetric measures.
With regard to the safety results of the study, although 
this was a pilot study of limited size and, therefore, not 
really comparable to larger studies reported in the literature 
for both drugs, the GOLDEN study supported the estab-
lished safety and tolerability profile of both drugs. The only 
SAE suspected of being related to the study treatment was 
a self-limiting, second-degree atrioventricular block after 
the first-dose of fingolimod, which is consistent with the 
known first-dose cardiovascular effects of the drug. Apart 
from this, first-dose monitoring was relatively eventless, 
although some patients required extended monitoring for 
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precautionary measures due to lowered heart rate. AEs sus-
pected of being related to treatment were in line with the 
tolerability and safety/tolerability profile of the two drugs 
as documented in the respective Summary of Product Char-
acteristics or reported in the literature. No significant differ-
ences between fingolimod and IFN β-1b groups with regards 
to safety parameters were evident except for the higher 
number of adverse events in the fingolimod group, and the 
greater proportion of patients experiencing an MS relapse 
in the IFN β-1b group.
In conclusion, the results of the GOLDEN study suggest 
that both fingolimod and IFN β-1b treatments were associ-
ated with improvements in all cognitive parameters, with 
some differences in the improvement patterns. Despite a dis-
advantage in terms of baseline characteristics and drop-out 
patterns, fingolimod treatment demonstrated significantly 
better effects than IFN β-1b on MRI parameters and relapse 
rate.
Also, although limited in size, the GOLDEN study 
confirms the favourable benefit–risk profile of fingolimod 
reported in previous studies.
Management of cognitive decline in MS, which substan-
tially alters patients’ quality of life and is the leading cause 
of occupational disability in patients with MS [44], is an area 
that still needs further research. Among others, additional 
studies are warranted to better understand the effects of 
DMTs on cognitive function and its correlation with under-
lying disease mechanisms.
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